Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
Major pharmaceutical multinationals are looking to collaborate with Indian drug firms, leveraging their cost-efficient manufacturing capabilities, robust supply chains, and innovative research potential. 31 July 2024
The Russian government will be ready to significantly increase state procurements of drugs against hepatitis C in case of reduction price for them both by global drugmakers and Russian pharmaceutical companies. 31 July 2024
March is Wilson disease awareness month – an autosomal recessive genetic disorder characterized by excess copper accumulation in the body.1 It is caused by a mutation in the ATP7B gene, with an estimated one in 90 people carrying the mutation.1 29 March 2022
On February 17, 2022, Dr Robert Califf was sworn in as US Food and Drug Administration Commissioner for the second time; his first term was from February 2016 to January 2017, under the Obama administration. 28 March 2022
The pharmaceutical industry is faced by a multi-dimensional challenge of revenues under pressure, increasing regulatory requirements which differ across localities, dispersed data sources, innovation in technology and staffing pressures. 23 March 2022
China’s Fosun Pharma’s biotech arm Henlius is preparing to get its PD1 antibody serplulimab into hospitals nationwide once it is approved in China, and supply its four approved biosimilars with enhanced manufacturing capacity, said Henlius chief executive Zhang Wenjie at a press meeting held in Shanghai on March 17. 22 March 2022
Innovative treatments and medicines developed by the pharmaceutical industry in Latin America not only save lives, but also create jobs, help reduce health spending and raise quality of life standards, The Pharma Letter’s local correspondent writes. 22 March 2022
Indian generic players may soon have access to a blockbuster cancer drug. The loss of exclusivity in the USA for Bristol Myers Squibb's Revlimid (lenalidomide) is helping several generic players to seek huge gains, with some in India entering unique settlements, reports The Pharma Letter’s India correspondent. 21 March 2022
Due to Russia’s military invasion of the Ukraine, global pharma companies are massively refusing to conduct clinical trials of their drugs in Russia, which means that the launch of these drugs in the local market will be impossible 19 March 2022
An Expert View from Jennifer Romanski, a principal of Porzio, Bromberg & Newman and a co-chair of its Life Sciences Compliance and Regulatory Counseling Department. She is also a senior vice president at Porzio Life Sciences, a wholly-owned subsidiary of the law firm. 18 March 2022
Global drugmakers have no plans to leave Russia, aiming to continue their work in the local market despite the ongoing military escalation in Ukraine and unprecedented sanctions imposed on the country by Western governments, according to recent statements by representatives of companies and some local media, reports The Pharma Letter’s local correspondent. 15 March 2022
Companies developing microbiome-based treatments have garnered a lot of interest recently, following many years of uncertainty over the approach. Dr James McIlroy, CEO of EnteroBiotix, spoke with The Pharma Letter about his firm's development strategy, and the broader potential for this therapy area. 9 March 2022
At the national level, drug pricing continues to be a hot button issue for lawmakers, drugmakers and patients in the USA. At the state level, could Prescription Drug Affordability Boards (PDAB) be the answer? 4 March 2022
Kathleen Rickard, chief medical officer, Verona Pharma, with an Expert View to educate other executives who are considering going down the remote/flexible route for clincial trials. 4 March 2022
Russian drugmaker and global pharma companies will significantly reduce the production of anti-COVID-19 vaccines, however the same plans are not considered in case of other drugs, according to recent statements by representatives of producers and some media, reports The Pharma Letter’s local correspondent. 1 March 2022
Are multinational pharmaceutical companies losing ground in India? The ongoing restructuring and overhaul taking place at several multinational drug companies based in India, including the sale of brands and the closing of non-core units, came up for discussion at a recent event, reports The Pharma Letter’s India correspondent. 1 March 2022
Bold investments in BlueRock, AskBio and Vividion have shown the ambition of Bayer’s new approach towards R&D, and another sign of intent was the German company’s appointment of Christian Rommel in late 2020. 28 February 2022